Back to top
more

Charles River Laboratories International (CRL)

(Delayed Data from NYSE)

$223.06 USD

223.06
473,731

+1.45 (0.65%)

Updated May 20, 2024 04:00 PM ET

After-Market: $223.03 -0.03 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (140 out of 249)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Charles River (CRL) Introduces Novel IgY-Based ELISA Kit

by Zacks Equity Research

Charles River's (CRL) HCP-ELISA is built on its HCP-GAPex service, enhancing the efficiency and efficacy of HCP assay development.

Charles River Laboratories (CRL) to Report Q4 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

InnovAge Holding Corp. (INNV) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of 36.36% and 1.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Charles River (CRL) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

The broad-based demand and meaningful price increases in the RMS business particularly in North America are expected to have contributed to Charles River's (CRL) top line in Q4.

Charles River's (CRL) New CDMO Tie-Up to Boost Clinical Trials

by Zacks Equity Research

Charles River's (CRL) latest partnership is expected to bring a potentially curative therapy, RZ-001, to HCC patients.

Charles River (CRL) to Develop RNA-based Therapy With New Pact

by Zacks Equity Research

Charles River's (CRL) new partnership will enable the clinical development of RNA-based anticancer gene therapy in liver cancer patients.

Charles River (CRL) to Advance DNA Programs With New Launch

by Zacks Equity Research

Charles River's (CRL) launch of the eXpDNA plasmid manufacturing platform is intended to support vaccine and advanced therapy clients through clinical trials and beyond.

Should You Buy Charles River Laboratories (CRL) After Golden Cross?

by Zacks Equity Research

Is it a good or bad thing when a stock experiences a golden cross technical event?

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) on robust performances across the RMS and DSA segments.

Charles River (CRL) Benefits From Price Rise Amid FX Woe

by Zacks Equity Research

Charles River's (CRL) RMS growth prospects are high, courtesy of accelerating growth for research model services and research models.

Charles River (CRL) Q3 Earnings Top Estimates, Margins Dip

by Zacks Equity Research

Headwinds associated with foreign exchange due to the strengthening of the U.S. dollar and interest expense due to a rising interest rate environment increase concerns for Charles River (CRL).

Charles River Laboratories (CRL) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Charles River (CRL) delivered earnings and revenue surprises of 4.78% and 1.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Teladoc (TDOC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Teladoc (TDOC) delivered earnings and revenue surprises of 23.73% and 0.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Charles River (CRL) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Charles River's (CRL) CRADLE initiative for small and large biopharmaceutical clients is anticipated to have maintained its growth momentum.

Henry Schein (HSIC) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

We expect the Condor Dental buyout to have a beneficial impact on Henry Schein's (HSIC) results in the to-be-reported quarter.

Hologic (HOLX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Hologic's (HOLX) interventional business is likely to have faced continued supply chain headwinds related to disposable biopsy needles, hampering its performance.

Abbott's (ABT) Q3 Earnings Top Estimates, 2022 EPS View Up (Revised)

by Zacks Equity Research

Abbott's (ABT) Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

IDEXX (IDXX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

IDEXX's (IDXX) CAG premium instrument placements are expected to have recorded significant growth in Q3 on the continued rise in Catalyst and premium hematology placements.

STERIS (STE) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

STERIS' (STE) Dental arm revenues are expected to have been impacted somewhat by supply chain challenges.

Abbott's (ABT) Q2 Earnings Top Estimates, 2022 EPS View Up

by Zacks Equity Research

Abbott's (ABT) Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Owing to the impact of the Russia-Ukraine war situation, supply chain constraints, as well as the inflationary situation, we expect Bio-Rad's (BIO) Life Science arm to experience a year-over-year decline.

What's in Store for Edwards Lifesciences (EW) in Q3 Earnings?

by Zacks Equity Research

Within the TAVR arm, Edwards Lifesciences (EW) is likely to have witnessed continued growth in procedures across the United States and worldwide.

Align Technology (ALGN) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Align Technology's (ALGN) Invisalign First for kids is gaining market share rapidly across all regions.